French cancer specialist Innate Pharma can remain independent, for now: CEO
Herve Brailly, CEO of Innate Pharma, attends the Reuters Biotech summit in Paris June 3, 2009. REUTERS/John Schults France’s Innate Pharma believes that its cash position and portfolio are sufficiently robust for the cancer drug company to remain independent f... More »
